The gut microbiome may trigger RA & predict methotrexate response. ACR Convergence 2025 experts discuss pathogenesis & drug efficacy.
Latest News
Differentiating POTS from Other Conditions
At a ACR Convergence 2025 session, two experts discussed POTS, the importance of considering dysautonomia when making a differential diagnosis & an interdisciplinary approach to treatment.
The Pros & Cons of AI
As the uses for artificial intelligence grow within rheumatology, so do the benefits and the concerns about the technology. In a session at ACR Convergence 2025, two experts discuss the research on both sides of the debate.
Lupus Nephritis: A Serious Manifestation of Systemic Lupus Erythematosus
In this review, some of the many abstracts on research into lupus nephritis presented at ACR Convergence 2025 are highlighted. The abstracts selected demonstrate the advances made on the early recognition of the condition, as well as offering some hope in terms of achieving better outcomes.
Lupus Nephritis from Bench to Bedside
Urinary biomarkers may have the potential to detect early treatment responses or failures in patients with lupus nephritis, according to Andrea Fava, MD. He and other experts discussed the latest research into lupus nephritis and how apply the recent ACR guideline to refractory cases.
President’s Corner: Reflections on the ACR’s 2025
Dr. Langford’s final column reflects on 2025’s advocacy, challenges & member teamwork. Click through to read the outgoing ACR president’s parting thoughts.
